短程放疗联合FOLFOXIRI保肛治疗直肠癌II期试验两年主要结局
该单臂II期研究评估剂量递增短程放疗(25 Gy/5次+5 Gy/1次推量)序贯8周期FOLFOXIRI能否提高高危直肠癌的临床完全缓解率。37例患者中9例(24%)内镜和MRI均达cCR并选择保肛,18例保肛者两年局部再生9例,两年无TME生存率26%。
要点
- 37例高危直肠癌中9例(24%)内镜和MRI均达cCR并选择保肛。
- 18例保肛者中9例两年内局部再生,两年无TME生存率26%。
- 年龄<50岁和T4疾病与未实现保肛显著相关。
核心结论
- 短程放疗加推量序贯FOLFOXIRI使约四分之一高危直肠癌患者实现保肛,年轻患者和T4疾病反应较差。
研究设计与样本
- 单臂II期研究,2020至2023年入组37例>T2N0M0或低位T2N0直肠癌成人患者。
- 干预为剂量递增短程放疗(25 Gy/5次+5 Gy/1次推量)序贯8周期FOLFOXIRI。
主要发现
- 27例(73%)至少具有一项高危特征(cT4、EMVI、N2、环周切缘受威胁、侧方淋巴结阳性)。
- 18例保肛者中9例自放疗开始两年内局部再生,两年无TME生存率26%。
- 未实现保肛的基线相关因素包括年龄<50岁和T4疾病。
- 治疗中期再分期时,实现保肛者持续淋巴结阳性、EMVI和内镜下可见肿瘤的可能性显著更低。
临床怎么用
- 治疗中期反应可能有助于及时指导治疗决策。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: As patients with rectal cancer with clinical complete response (cCR) after neoadjuvant therapy may be safely spared Total Mesorectal Excision (TME), strategies to maximize cCR are needed. MATERIALS AND METHODS: We conducted a single-arm phase II study to determine whether dose-escalated short-course radiotherapy (25 Gy/5 fractions + 5 Gy/1 fraction boost) followed by eight cycles of FOLFOXIRI increased cCR rates among adult patients with > T2N0M0 or low T2N0 rectal cancer. RESULTS: Between 2020 and 2023, we enrolled 37 patients, of whom 27 (73 %) had at least one high-risk feature (cT4, extramural vascular invasion [EMVI], N2, threatened circumferential resection margin, positive lateral node). At primary endpoint assessment, nine (24 %) patients had cCR on both endoscopy and MRI, and pursued organ preservation (OP). Fourteen (38 %) patients had cCR only on endoscopy, nine of whom pursued OP. Of the 18 patients who pursued OP, nine had local regrowth at two years from radiotherapy start, with two-year TME-free survival of 26 %. Baseline factors significantly associated with not achieving OP included age < 50 years and T4 disease. At mid-treatment restaging, patients who achieved OP were significantly less likely to have persistent node positivity, EMVI, and endoscopically visible tumor. Grade 3+ adverse events at least possibly attributed to chemotherapy and radiotherapy occured in 51% and 43% of patients, respectively. CONCLUSION: Short-course radiotherapy with a boost followed by FOLFIXIRI results in OP in one-quarter of patients with high-risk rectal cancer, with poorer response among younger patients and T4 disease. Mid-treatment response may help guide timely decision-making regarding treatment.
引用
- Klebaner D, Brown E, Fisher GA, et al. Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX): Two-Year primary outcome analysis. Radiother Oncol. 2025. PMID: 40209856. doi:10.1016/j.radonc.2025.110884
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。